AI Terminal
GENINCODE PLC
Earnings Release • Aug 26, 2025
7669_rns_2025-08-26_6b043a38-cdac-45c9-9d7d-d8d2e4897045.html
Earnings Release
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5179W
GENinCode PLC
26 August 2025
26 August 2025
GENinCode Plc
("GENinCode" or the "Company")
Trading update - H1 2025
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk of ovarian cancer announces a trading update for the 6 months ending 30 June 2025. The first half of 2025 saw continued strengthening of business, with revenues up 15% to £1.6m (30 June 2024 £1.4m) driven by growth across the UK, EU and US business. Gross profit margin remained firm at 53%, (30 June 2024 53%) with losses of £2.4m (30 June 2024 (£2.4m)). Cash at the end of June 2025 was £2.4m (30 June 2024 £2.9m). Trading remains broadly in line with the Board's overall expectations for the full year, with a busy second half period ahead.
FDA De Novo discussions continue to progress with work ongoing to close out the short list of remaining deficiencies. Collaboration discussions on potential US and EU test distribution are also advancing with a major distributer. New clinical data on CARDIO inCode-Score (polygenic risk score) was presented by Kaiser Permanente at the American Society of Preventive Cardiology (ASPC) in Boston in early August with a further presentation at this week's European Society of Cardiology (ESC) Annual Congress in Madrid (Aug 29th - Sept 1st) on the clinical importance of CARDIO inCode-Score in the modulation of cholesterol risk for coronary heart disease.
The Company will present its 2025 Interim Report at the end of September with the reporting date to be confirmed in due course.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | ||
| Matthew Walls, CEO Paul Foulger, CFO |
|||
| Cavendish Capital Markets Limited | Tel: 020 7397 8900 | ||
| Giles Balleny (Corporate Finance) | |||
| Nigel Birks (Life Sciences Specialist Sales) Harriet Ward (Corporate Broking) |
|||
| Dale Bellis / Michael Johnson (Sales) | |||
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | ||
| Anna Dunphy / Rachel Broad / Marcus Ulker | |||
About GENinCode:
GENinCode Plc is a UK based company specialising in prevention of cardiovascular disease and surveillance testing for ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode operates business units in the UK, Europe through GENinCode S.L.U., and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading diagnostics and risk assessment for precision medicine treatment and preventive care. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTZZGZRZDRGKZM